Nanotechnology Now - Press Release: "Tiny magnets offer breakthrough in gene therapy for cancer"

Home > Press > Tiny magnets offer breakthrough in gene therapy for cancer

Abstract:
A revolutionary cancer treatment using microscopic magnets to enable 'armed' human cells to target tumours has been developed by researchers at the University of Sheffield.

Tiny magnets offer breakthrough in gene therapy for cancer

UK | Posted on April 18th, 2008

Research published online today (17 April 2008) in the journal, Gene Therapy, shows that inserting these nanomagnets into cells carrying genes to fight tumours, results in many more cells successfully reaching and invading malignant tumours.

Using human cells as delivery vehicles for anti-cancer gene therapy has long been an attractive approach for treating tumours, but these cells usually reach tumours in insufficient numbers to effectively attack them. Now, a new 'magnetic targeting' method has been developed to overcome this problem by Professor Claire Lewis at the University of Sheffield, alongside colleagues at the Universities of Keele and Nottingham.

The technique involves inserting nanomagents into monocytes - a type of white blood cell used to carry gene therapy - and injecting the cells into the bloodstream. The researchers, funded by the Biotechnology and Biological Sciences Research Council (BBSRC), then placed a small magnet over the tumour to create a magnetic field and found that this attracted many more monocytes into the tumour.

Professor Lewis, explains: "The use of nanoparticles to enhance the uptake of therapeutically armed cells by tumours could herald a new era in gene therapy - one in which delivery of the gene therapy to the diseased site is much more effective. This new technique could also be used to help deliver therapeutic genes in other diseases like arthritic joints or ischemic heart tissue."

Professor Nigel Brown, BBSRC Director of Science and Technology, said: "This exciting work could have huge implications in healthcare. Fundamental bioscience research may sometimes seem to have little relevance to everyday life, but understanding the basic workings of the human body and harnessing nanoscale technology has resulted in a process of great potential in tumour therapy."

The team are now looking at how effective magnetic targeting is at delivering a variety of different cancer-fighting genes, including ones which could stop the spread of tumours to other parts of the body.

Notes for Editors: This research is published online in Gene Therapy today and will be published in the journal Gene Therapy on 3 June 2008.

The research was carried out jointly by Professor Claire Lewis and Dr Munitta Muthana, University of Sheffield, Professor Jon Dobson and Dr. Neil Farrow, Keele University and Professor Helen Byrne and Dr Giles Richardson, University of Nottingham.

The research was funded by the Biotechnology and Biological Sciences Research Council.

About BBSRC
The Biotechnology and Biological Sciences Research Council (BBSRC) is the UK funding agency for research in the life sciences. Sponsored by Government, BBSRC annually invests around Ł380 million in a wide range of research that makes a significant contribution to the quality of life for UK citizens and supports a number of important industrial stakeholders including the agriculture, food, chemical, healthcare and pharmaceutical sectors.

####

About University of Sheffield
A hundred years ago the founding motto of the University was Rerum Cognoscere Causas, meaning "To discover the causes of things". A century later the knowledge landscape has shifted dramatically.

Our research ethos continues to uphold the ideals of discovery whilst acknowledging new ways of acquiring, investigating, developing and applying knowledge.

For more information, please click here

Contacts:
Lindsey Bird
Media Relations Officer
44 0114 2225338

If you have a comment, please Contact us.

Issuers of news releases, not 7th Wave, Inc. or Nanotechnology Now, are solely responsible for the accuracy of the content.

Bookmark: